Frontiers in Genetics (Feb 2016)

The MiRNA Journey from Theory to Practice as a CNS Biomarker

  • Nicoleta eStoicea,
  • Amy eDu,
  • Dorothy eLakis,
  • Courtney eTipton,
  • Carlos E Arias Morales,
  • Sergio Daniel Bergese,
  • Sergio Daniel Bergese

DOI
https://doi.org/10.3389/fgene.2016.00011
Journal volume & issue
Vol. 7

Abstract

Read online

MicroRNAs (miRNAs), small nucleotide sequences that control gene transcription, have the potential to serve an expanded function as indicators in the diagnosis and progression of neurological disorders. Studies involving debilitating neurological diseases such as, Alzheimer’s disease, multiple sclerosis, traumatic brain injuries, Parkinson’s disease and CNS tumors, already provide validation for their clinical diagnostic use. These small nucleotide sequences have several features, making them favorable candidates as biomarkers, including function in multiple tissues, stability in bodily fluids, a role in pathogenesis, and the ability to be detected early in the disease course. Cerebrospinal fluid, with its cell-free environment, collection process that minimizes tissue damage, and direct contact with the brain and spinal cord, is a promising source of miRNA in the diagnosis of many neurological disorders. Despite the advantages of miRNA analysis, current analytic technology is not yet affordable as a clinically viable diagnostic tool and requires standardization. The goal of this review is to explore the prospective use of CSF miRNA as a reliable and affordable biomarker for different neurological disorders.

Keywords